# Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Study · id `cardio:ct-nct04263922` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04263922](<https://clinicaltrials.gov/study/NCT04263922>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04263922

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 466 participants.

## Technical summary

Registry record NCT04263922. Randomized; double masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 466 participants (planned count; ClinicalTrials.gov record NCT04263922, source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)
- Started: 2020-06-30 (actual) (ClinicalTrials.gov record NCT04263922, source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)
- Primary completion: 2025-10-31 (anticipated) (ClinicalTrials.gov record NCT04263922, source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)
- Completion: 2026-03-30 (anticipated) (ClinicalTrials.gov record NCT04263922, source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04263922, source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04263922-2024-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Huaiqihuang granules
- Intervention (Drug): Valsartan capsule
- Lead sponsor: The First Affiliated Hospital of Dalian Medical University
- Lead sponsor class: OTHER
- Collaborator: Huazhong University of Science and Technology
- Collaborator class: OTHER
- Collaborator: LinkDoc Technology (Beijing) Co. Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of Dalian Medical University (`cardio:org-the-first-affiliated-hospital-of-dalian-medical-university`)
- Registry lists this organization as a collaborator: Huazhong University of Science and Technology (`cardio:org-huazhong-university-of-science-and-technology`)

## Provenance

Content hash: 8a21e48c6e4641e0baed00c102469cd3b7093354178158a8f51eb28f30303b4a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
